Risk adjusted net present value: What is the current valuation of Tenaya Therapeutics’s TN-401?

TN-401 is a gene therapy commercialized by Tenaya Therapeutics, with a leading Phase I program in Cardiomyopathy.

Pfizer’s Elrexfio, Astellas’ Veozah among new drugs recommended for authorization by European regulatory committee

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) this week recommended seven new drugs for authorization, including Pfizer’s potential multiple myeloma

October 14, 2023

Layoffs at Sumitomo; Galderma and L’Oréal strike a deal

Plus, news about Eiger BioPharmaceuticals: Sumitomo cuts workers: The Japanese pharma is laying off 53 people in Marlborough, MA, according to an August 1 …

August 6, 2024

Filament Health Uplisting To NASDAQ In A $210M SPAC Deal

Canadian clinical-stage natural psychedelics company Filament Health FLHLF has entered into a definitive agreement with Jupiter Acquisition Corp. JAQC, a Special Purpose Acquisition Company (SPAC) for the creation of

July 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.